Lotus Clinical Research — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Lotus Clinical Research is a private, revenue-generating CRO that provides integrated clinical trial services with a unique operational model. Its key advantage is the vertically integrated site network from its sister company, ERG, which includes over 20 owned research units, facilitating rapid trial initiation and access to patient populations. Backed by a team of over 47 MDs and 12 PhDs/PsyDs with experience in over 3,400 studies, Lotus aims to accelerate development timelines in complex therapeutic areas like neuroscience and metabolic diseases. The company operates globally and claims contribution to 32 FDA approvals since its founding.

Central Nervous System (CNS)PainObesityMetabolic Diseases

Technology Platform

Integrated operational platform combining a full-service Contract Research Organization (CRO) with a commonly-owned, large-scale network of clinical research sites (Evolution Research Group). This includes priority access to over 20 owned sites, 400+ beds, and specialized facilities, coupled with a large Scientific Leadership Team for protocol design and risk mitigation.

Opportunities

The booming clinical trial markets in obesity/metabolic diseases (driven by GLP-1 drugs) and complex CNS disorders present massive demand for specialized CRO services.

Its integrated site network model directly addresses the industry's biggest pain points—slow patient recruitment and site activation—offering a compelling speed-to-market advantage for sponsors.

Global expansion through strategic CRO alliances can scale this model without significant capital expenditure.

Risk Factors

High dependency on the performance and exclusive relationship with the Evolution Research Group site network creates operational and strategic vulnerability.

Intense competition from large, global CROs with greater resources and broader therapeutic expertise poses a significant market capture challenge.

The integrated model concentrates reputational risk, where any quality or compliance issue at an ERG site directly damages the Lotus CRO brand.

Competitive Landscape

Lotus competes with large, full-service global CROs (e.g., IQVIA, ICON, Labcorp) and smaller, niche neuroscience or metabolic CROs. Its key differentiation is the vertically integrated site network, a feature most large CROs do not own, giving it a potential edge in speed and operational control for US-based trials. However, large CROs counter with unparalleled global scale, vast data assets, and broader service offerings.

More companies in Neuroscience & CNS →More companies in United States →